MINNEAPOLIS, February 17, 2021 / PRNewswire / – Metavention, Inc. announces the initiation of an FDA-cleared clinical investigation, DeLIVER (NCT04285554), for the company’s iRF intravascular denervation system for the purpose of determining safety in patients with Type 2 Diabetes (T2D).
Doctors at HSHS St. John’s Hospital in Springfield, IL treated the first patient in the US DeLIVER study. “We are excited to participate in this breakthrough, minimally invasive treatment for patients with type 2 diabetes.” Krishna Rocha-Singh, MD, Scientific Director of the Prairie Heart Institute. “There remains a significant clinical need for improved treatment options in the management of type 2 diabetes. The prospect of adding endovascular therapy to complement the care of this challenging patient population is compelling and exciting.”
People with T2D have abnormal levels of sugar, also known as glucose, in their blood. The patient’s liver is often a major contributor to this unwanted glucose. The liver plays a central role in properly regulating glucose levels, but excessive release of glucose into the bloodstream by the liver, triggered by overactive sympathetic nerve signals, can be a major limitation in the control of T2D. Metavention’s patented iRF denervation system was developed as a unique transcatheter procedure that uses radio frequency energy to inhibit overactive sympathetic nerve signals to the liver, thereby improving overall glucose control.
“T2D continues to be a global epidemic. Patients are expected to accept lifelong daily use of complex and expensive drugs with a high likelihood of disease progression resulting in insulin dependence and serious health complications,” he said Todd Berg, CEO of Metavention. “Metavention’s iRF denervation system has the potential to offer patients a fundamentally new treatment option for managing their T2D by targeting an underlying cause of their disease.”
About type 2 diabetes
T2D is a chronic, progressive disease that affects more than 400 million people worldwide. Despite significant treatment efforts with lifestyle changes and medication, about 50% of patients fail to achieve adequate glycemic control, placing them at a higher risk of complications. Possible complications of T2D include an increased risk of heart disease, stroke, high blood pressure and narrowing of the blood vessels (atherosclerosis), nerve damage, kidney failure, glaucoma and blindness.
About Metavention Inc.
Metavention, Inc., developer of the iRF denervation system, is a privately held medical device company headquartered in Minneapolis, Minnesota. This procedure is intended to be an adjunct therapy that enables improved control of T2D, high blood pressure and other metabolic diseases. Further information is available at www.metavention.com.
CAUTION – The iRF Denervation System is an examination device and is sold by Federal (or United States) Law of Investigation.